Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11486002 | 0.98 | APLNR (0.39) | APLNREPHX1HIF1A | |
| SCHEMBL11492207 | 0.98 | APLNR (0.39) | APLNREPHX1HIF1A | |
| SCHEMBL11485996 | 0.98 | APLNR (0.39) | APLNREPHX1HIF1A | |
| SCHEMBL11485998 | 0.98 | APLNR (0.39) | APLNREPHX1HIF1A | |
| SCHEMBL11492208 | 0.98 | APLNR (0.39) | APLNREPHX1HIF1A | |
| SCHEMBL4048773 | 0.78 | ALDH1A1 (0.48) | EPHX1HIF1A | |
| SCHEMBL11508353 | 0.78 | APLNR (0.50) | APLNREPHX1HIF1A | |
| SCHEMBL5439892 | 0.74 | ALDH1A1 (0.43) | — | |
| SCHEMBL11582155 | 0.71 | APLNR (0.39) | APLNREPHX1HIF1A | |
| SCHEMBL13310980 | 0.71 | APLNR (0.42) | APLNREPHX1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329718-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY13 | APLNR 949/4885EPHX1 917/4885HIF1A 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.